All In MedTech

Device Trial Radar · NCT02767401

The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)

Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

200

Actual

Start

Sep 15, 2015

Primary completion

Aug 15, 2018

Study completion Dec 15, 2018

Sponsor

Lead sponsor
The First Affiliated Hospital of Dalian Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Anzhen Hospital; First Hospital of China Medical University; Nanfang Hospital, Southern Medical University
First posted
May 10, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of percutaneous coronary intervention (PCI) on myocardial viability in coronary artery disease patients with single coronary total occlusion (CTO) lesions.

Conditions

  • Hibernation, Myocardial
  • Complete Occlusion of Coronary Artery

Interventions

  • stenting or balloon expansionDevice

    all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)

  • aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betalocDrug

    Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes to myocardial viabilityTime frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.